Evidence map›Paper›PMID 34592951›Full record

Trial reportBMC medical research methodology2021

Sequential Multiple Assignment Randomized Trial (SMART) to identify optimal sequences of telemedicine interventions for improving initiation of insulin therapy: A simulation study.

Xiaoxi Yan, David B Matchar, Nirmali Sivapragasam, John P Ansah, Aastha Goel, Bibhas Chakraborty

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC medical research methodology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoxi YanCentre for Quantitative Medicine. Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore. xiaoxi.yan@u.duke.nus.edu.
David B MatcharHealth Services and Systems Research Department, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
Nirmali SivapragasamHealth Services and Systems Research Department, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
John P AnsahHealth Services and Systems Research Department, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
Aastha GoelHealth Services and Systems Research Department, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
Bibhas ChakrabortyCentre for Quantitative Medicine. Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo examine the value of a Sequential Multiple Assignment Randomized Trial (SMART) design compared to a conventional randomized control trial (RCT) for telemedicine strategies to support titration of insulin therapy for Type 2 Diabetes Mellitus (T2DM) patients new to insulin.

methodsMicrosimulation models were created in R using a synthetic sample based on primary data from 63 subjects enrolled in a pilot study of a smartphone application (App), Diabetes Pal compared to a nurse-based telemedicine strategy (Nurse). For comparability, the SMART and an RCT design were constructed to allow comparison of four (embedded) adaptive interventions (AIs).

resultsIn the base case scenario, the SMART has similar overall mean expected HbA1c and cost per subject compared with RCT, for sample size of n = 100 over 10,000 simulations. SMART has lower (better) standard deviations of the mean expected HbA1c per AI, and higher efficiency of choosing the correct AI across various sample sizes. The differences between SMART and RCT become apparent as sample size decreases. For both trial designs, the threshold value at which a subject was deemed to have been responsive at an intermediate point in the trial had an optimal choice (i.e., the sensitivity curve had a U-shape). SMART design dominates the RCT, in the overall mean HbA1c (lower value) when the threshold value is close to optimal.

conclusionsSMART is suited to evaluating the efficacy of different sequences of treatment options, in addition to the advantage of providing information on optimal treatment sequences.

Indexed as

Diabetes Mellitus, Type 2TelemedicineHumansInsulinPilot ProjectsSample SizeInsulindiabetesoptimal adaptive interventionsSequential treatment designstelemedicine

Identifiers

PMID34592951
PMCPMC8481760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.